| Issue Date |
Title |
Author(s) |
| Jun-2021 |
Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study |
Dou, Xuelin;Zheng, Fangyuan;Zhang, Liqiang;Jin, Jie;Zhang, Yanli;Liu, Bingcheng;Meng, Li;Zhu, Xiaofan;Lu, Zesheng;Jia, Yueping;Liu, Huilan;Lin, Hai;Zhou, Li;Zhao, Xielan;Yang, Wei;Sun, Hui;Qian, Sixuan;Ma, Hongxia;Du, Xin;Bai, Qingxian;Xu, Na;Meng, Fanjun;Jia, Zhilin;Di, Haixia;Zhang, Leping;Jiang, Qian |
| 2017 |
Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study |
Ji, Yu;Song, Yongping;Zhou, Fang;Liu, Ting;Jiang, Ming;Zhao, Xielan;Huang, Xiaojun |
| 15-Jul-2020 |
Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study |
Jiang, Bo;Ke, Xiaoyan;Zhang, Qingyuan;Xu, Wei;Su, Hang;Huang, Jie;Zhang, Mingzhi;Wang, Huaqing;Jin, Chuan;Zhu, Jun;Liu, Li;Cai, Zhen;Zhao, Xielan;Zhou, Jianfeng;Zhang, Xiaohong;Liu, Jing;Zhou, Hui;Yu, Jie;Sun, Xing;Qi, Junyuan;Qiu, Lugui |
| 16-Apr-2020 |
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma |
Shi, Yuankai;Song, Yongping;Qin, Yan;Zhang, Qingyuan;Han, Xiaohong;Hong, Xiaonan;Wang, Dong;Li, Wei;Zhang, Yang;Feng, Jifeng;Yang, Jianmin;Zhang, Huilai;Jin, Chuan;Yang, Yu;Hu, Jianda;Wang, Zhao;Jin, Zhengming;Su, Hang;Wang, Huaqing;Yang, Haiyan;Fu, Weijun;Zhang, Mingzhi;Zhang, Xiaohong;Chen, Yun;Ke, Xiaoyan;Liu, Li;Yu, Ding;Chen, Guo'an;Wang, Xiuli;Jin, Jie;Sun, Tao;Du, Xin;Cheng, Ying;Yi, Pingyong;Zhao, Xielan;Ma, Chaoming;Cheng, Jiancheng;Chai, Katherine;Luk, Alvin;Liu, Eugene;Zhang, Xin |
| 2015 |
Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma |
Shi, Yuankai;Dong, Mei;Zhu, Jun;Zhou, Daobin;Huang, Huiqiang;Tu, Ping;Zhang, Weijing;Hong, Xiaonan;Zhao, Xielan;Sun, Jianfang;Liu, Yuehua;Qiu, Lugui;Shen, ZhiXiang;Feng, Jifeng;Ke, Xiaoyan |
| 2015 |
Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma |
Shi, Yuankai;Dong, Mei;Zhu, Jun;Zhou, Daobin;Huang, Huiqiang;Tu, Ping;Zhang, Weijing;Hong, Xiaonan;Zhao, Xielan;Sun, Jianfang;Liu, Yuehua;Qiu, Lugui;Shen, ZhiXiang;Feng, Jifeng;Ke, Xiaoyan |
| 2015 |
Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL) |
Wang, Jianxiang;Mi, Yingchang;Jiang, Bin;Chen, Xiequn;Ji, Chunyan;Li, Yan;Zhao, Xielan;Lai, Yongrong;Hu, Yu;Tang, Aiping;Liu, Ting;Jin, Jie;Li, Junmin;Yang, Linhua;Li, Jinyong;Meng, Fanyi |
| 2015 |
Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL) |
Wang, Jianxiang;Mi, Yingchang;Jiang, Bin;Chen, Xiequn;Ji, Chunyan;Li, Yan;Zhao, Xielan;Lai, Yongrong;Hu, Yu;Tang, Aiping;Liu, Ting;Jin, Jie;Li, Junmin;Yang, Linhua;Li, Jinyong;Meng, Fanyi |
